| Ticker |
IGC
|
| CIK | 0001326205 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 10224 FALLS ROAD, POTOMAC, MD, 20854 |
| Website | igcpharma.com |
| Phone | 301-983-0998 |
| CEO | Ram Mukunda |
| Employees | 61 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's TrialPOTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 /IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, reported its financial ... IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue EstimatesIGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +33.33% and -0.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue EstimatesHyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and -7.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat EstimatesVerrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +102.86% and +154.04%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease ... |
